Metrion Biosciences awarded £200k funding to further develop in-house drug discovery pipeline

6 Feb 2018

Funding will support further development of recently acquired small molecule assets for treatment of autoimmune disease.

Metrion Biosciences has been awarded £200k funding under the Innovate UK Biomedical Catalyst Feasibility Award scheme. The funding will be used to support further development of Metrion’s in-house drug discovery pipeline.

Metrion Biosciences awarded £200k funding to further develop in-house drug discovery pipeline

The funding will enable further preclinical development activities to be undertaken on the portfolio of small molecule potassium inhibitors acquired by Metrion from Japan Tobacco, with the aim of delivering a ‘best in class’, orally bioavailable, small molecule potassium channel inhibitor for the safe and effective treatment of a range of autoimmune diseases. This project is the first of a series of potassium channel inhibitor programmes Metrion has planned, which are designed to deliver proof of concept data on immune-sparing drug candidates, for treatment of autoimmune and neurodegenerative diseases.

Marc Rogers, Chief Scientific Officer, Metrion Biosciences, said: “We are pleased to receive this support from the Biomedical Catalyst scheme, which recognises Metrion’s contribution to R&D and drug discovery in the UK. Our team has extensive experience in the field of potassium ion channel drug discovery, having been responsible for discovery and development of three novel potassium channel therapeutics for the treatment of cardiac atrial fibrillation. We are excited to begin work on this project.”

Read More

Related news

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

Oxford Genetics signs major supply and licensing agreement for CRISPR engineered mammalian cell lines

8 Aug 2018

Company moves away from manual processing in favour of automated, scalable platforms.

Read more 
A new era for migraine patients

A new era for migraine patients

6 Aug 2018

EU approves Novartis's Aimovig, a first-of-its-kind treatment specifically designed for migraine prevention.

Read more 
WuXi STA and Antengene sign development and manufacturing agreement

WuXi STA and Antengene sign development and manufacturing agreement

24 Jul 2018

WuXi STA chosen for its end-to-end CMC platform for new drug development.

Read more 
ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

ProBioGen and Pionyr initiate 2nd immuno-oncology contract development and manufacturing project

18 Jul 2018

Parallel cell line development and analysis will allow for optimal cell line selection while compressing the development timeline.

Read more 
New screening company exploits the latest advances in microfluidics and 3D culture

New screening company exploits the latest advances in microfluidics and 3D culture

19 Jul 2018

The ability to micro size drug-cell interactions will allow pharmaceutical and biotech companies to do 100x more testing for the same money spent as well as increasing productivity.

Read more 
Natural lipid acts as potent anti-inflammatory

Natural lipid acts as potent anti-inflammatory

10 Jul 2018

Scientists see therapeutic potential against bacteria, viruses.

Read more 
Plasticell leads gene therapy manufacturing consortium

Plasticell leads gene therapy manufacturing consortium

3 Jul 2018

Consortium to develop advanced technologies for the manufacturing of ex vivo gene therapies.

Read more 
Follicum develops new direct-to-scalp formulation

Follicum develops new direct-to-scalp formulation

27 Jun 2018

The topical treatment for hair loss boasts a 'commercial' formulation.

Read more 
Collaboration to provide GMP-based services

Collaboration to provide GMP-based services

19 Jun 2018

Researchers to benefit by receiving a rapid and cost-effective scaled supply of new compounds.

Read more 
Locate Therapeutics secures £2 million to fast-track development of innovative cell therapy programs

Locate Therapeutics secures £2 million to fast-track development of innovative cell therapy programs

5 Jun 2018

TAOS matrix system and products hailed as potential ‘game changers’ in the field of regenerative medicine.

Read more